Navigation Links
New study shows promise in reducing surgical risks associated with surgical bleeding
Date:8/13/2007

CHICAGO (August 10, 2007) Surgeons may have a new patient safety tool to stop moderate surgical bleeding without some of the concerns associated with the current standard blood-clotting treatment. New research published in the August issue of the Journal of the American College of Surgeons shows that recombinant human thrombin (rhThrombin) reduces the risk of surgical complications associated with the use of plasma-derived bovine thrombin (bThrombin), which is currently the only commercially available stand-alone thrombin used to improve clotting during surgical procedures and stop bleeding.

Each year, bThrombin is used to treat more than one million patients who undergo surgical procedures in the United States. However, approximately 20 percent of these patients develop antibodies against bovine coagulation factors that can cross-react with human coagulation proteins and possibly lead to adverse effects, including severe bleeding and thrombosis. Due to these safety concerns, rhThrombin was developed as an alternative to bThrombin.

We constantly look for new ways to reduce risks in surgery and stopping surgical bleeding safely and effectively is of foremost interest to surgeons. The results from this phase III trial show that we can stop bleeding in 95 percent of patients within 10 minutes and do so without introducing foreign proteins that can carry greater risk of development of antibodies, said William C. Chapman, MD, FACS, Department of Surgery, Washington University, St. Louis (MO) School of Medicine. Im most encouraged by the increasing evidence that recombinant technology is safe and effective because it means that we may be able to avoid using blood or blood products from other people or animals and automatically diminish the risk of infection and the associated immunologic responses that have been noted in the past.

The randomized, double-blind comparative study included 411 patients who underwent surgical procedures at 34 U.S. medical centers across the country. One group of patients (n=206) was treated with bThrombin and a second group (n=205) was treated with rhThrombin, both of which were applied topically to the bleeding site(s) in combination with an absorbable gelatin sponge. The primary endpoint was the time it took for hemostasis to occur, as measured by the incidence of hemostasis within 10 minutes. Secondary endpoints included the incidence and severity of adverse events and the incidence of antiproduct antibodies.

The study demonstrated that both rhThrombin and bThrombin had comparable efficacy, with 95 percent of patients in each treatment group achieving hemostasis within 10 minutes. The two treatments had similar safety profiles, although antibody development was significantly lower in patients treated with rhThrombin compared with bThrombin (1.5 percent versus 21.5 percent, respectively).


'/>"/>

Contact: Sally Garneski
pressinquiry@facs.org
312-202-5409
Weber Shandwick Worldwide
Source:Eurekalert

Related medicine news :

1. Gene study links endometriosis, infertility
2. Study reveals how stress can make you sick
3. Study points out that HIV vaccine may not be accepted easily
4. A new study surpasses Gene Therapy Hurdle
5. Tomato Sauce reduces Cancer Risk- Study
6. A question on study of Adult Stem Cell
7. Study on obesity and heart failure
8. National Lung Study in the process
9. Marijuana gateway theory strengthened by study of twins
10. Old theory of adaptation confirmed by new study
11. Study casts doubt on keyboard ills
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... AL (PRWEB) , ... December 02, 2016 , ... ... from across the Dothan-Wiregrass Area in Alabama are expected to attend the UNCF ... Schmitz, will help provide scholarship funds for area students and operating support to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and Related ... those affected by autism spectrum disorder (ASD) and other developmental disabilities. The group, which ... give parents and other caregivers the opportunity to share stories and advice, seek help, ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs ... patients must find the one that works for them. When an inventor from Suisun ... that worked and decided to share it with others. , He developed a prototype ...
(Date:12/2/2016)... York, NY (PRWEB) , ... December 02, 2016 , ... ... high school and while 84 percent of parents report speaking with their child about ... pornography and sexually transmitted diseases. , Mediaplanet is proud to announce the launch of ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd ... Beach Resort and Spa in Honolulu, offering local frontline clinicians the opportunity to ... , The demand for supplemental training related to pain management has surged ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 Research and Markets has announced the ... their offering. ... R&D Drug Pipeline Database: 1-Year ... Drug Pipeline Database provides 24/7 online access to information about more ... and on investigational drug candidates in research & development. ...
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories, un líder mundial ... el INSTI HIV Self Test , a los miembros de la Kenya ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue ...
(Date:12/2/2016)...  LifeVac, the revolutionary device that has successfully rescued ... Training and Support Services (ERTSS) training programs. ... part of the ERTSS mission to save lives," said ... "Having an established network of expert trainers demonstrating how ... our efforts to spread LifeVac,s message that choking deaths ...
Breaking Medicine Technology: